Drug Trial Radar · NCT05858788
A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.
Last checked: Nov 19, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
May 15, 2023
Primary completion
Jul 17, 2023
Study completion Jul 17, 2023
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a cross-over, Phase 1, 3-treatment period single sequence study. The purpose of this study is to characterize pharmacokinetics (PK), safety, and tolerability of single ascending oral doses of SAR441566 in healthy male Japanese participants, 18-55 years of age.
Conditions
- Rheumatoid Arthritis
Interventions
SAR441566Drug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: CmaxTime frame: From Day 1 to Day 5 of each period (5 days per period)
- Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: AUClastTime frame: From Day 1 to Day 5 of each period (5 days per period)
- Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: AUCTime frame: From Day 1 to Day 5 of each period (5 days per period)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International-Site Number:8400001
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.